# Author Index to Volume 22

Abalan F, Barberger-Gateau P, Manciet G, Dartigues J-F. Plasma volume in senile and presenile Alzheimer's disease, 114-le
Abbott RM. *See* Joyce PR
Abelman E. *See* Amsterdam JD
Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: Review and analysis of 115 cases, 1004
Adler LE. *See* Baker N
Aizenberg D. *See* Modai I
Akil H. *See* Meador-Woodruff JH
Akkerhuis GW. *See* Minderaa RB
Albright A. *See* Berrettini WH
Alessi NE. *See* Dilsaver SC
Alexopoulos GS. *See* Young RC
Ally J. *See* Yassa R
Almay BGL, Haggendal J, von Knorring L, Oreland L. 5-HIAA and HVA in CSF in patients with idiopathic pain disorders, 403
Almoguera I. *See* Ayuso-Gutiérrez JL
Alvarez E. *See* Sarrias MJ
Amidsen A. The history of lithium, 522-le
Amidsen A. Pearson's correlation coefficient, *p*-value, and lithium therapy, 926-le
Amsterdam JD, Settle RG, Doty RL, Abelman E, Winokur A. Taste and smell perception in depression, 1481
Ancoli-Israel S, Kripke DF, Mason W. Characteristics of obstructive and central sleep apnea in the elderly: An interim report, 741
Anderson GM. *See* Minderaa RB
Angrist B, Corwin J, Bartlik B, Cooper T. Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects, 1357
Ansseau M. *See* Demey-Ponsart E
Ansseau M. *See* D'haenen H
Anton RF. Urinary free cortisol in psychotic depression, 24
Armstrong J. *See* Pettegrew JW
Artigas F. *See* Sarrias MJ
Asnis GM. *See* van Praag HM
Ayuso-Gutiérrez JL, Cabranes JA, Garcia-Camba E, Almoguera I. Pituitary-adrenal disinhibition and suicide attempts in depressed patients, 1409

Backus FI. *See* Raskind MA
Baker N, Adler LE, Franks RD, Waldo M, Berry S, Nagamoto H, Muckle A, Freedmen R. Neurophysiological assessment of sensory gating in psychiatric inpatients: Comparison between schizophrenia and other diagnoses, 603
Ballantine HT, Bouckoms AJ, Thomas EK, Giriunas IE. Treatment of psychiatric illness by stereotactic cingulotomy, 807
Balon R. *See* Pohl R
Balon R. *See* Yeragani VK
Barberger-Gateau. *See* Abalan F
Bardakjian J. *See* Berrettini WH
Barkai AI, Nelson HD. Alterations by antidepressants of cerebrospinal fluid formation and calcium distribution dynamics in the intact rat brain, 892
Barnas C. *See* Fleischhacker WW
Barnett AL Jr. *See* Berrettini WH
Barron JL. *See* Sandman CA
Bartlik B. *See* Angrist B
Becker RE. *See* Moriearty PL
Beckmann H. *See* Fritze J
Beckmann H. *See* Lesch K-P
Begleiter H. *See* Brecher M
Beil C. *See* Herholz K
Bell J. *See* Keshavan M
Belmaker RH. *See* Schreiber G
Benkelfat C. *See* Poirier MF
Berger M. *See* Krieg J-C
Berger M. *See* Weigand M
Berger M, Bossert S, Krieg J-C, Dirlich G, Ettmeier W, Schrieber W, von Zerssen D. Interindividual differences in the susceptibility of the cortisol system: An important factor for the degree of hypercortisolism in stress situations, 1327
Berger PA. *See* Whiteford HA

*Abbreviations*
ed: Editorial
le: Letter to the Editor

Bering B, Moises HW, Müller WE. Muscarinic cholinergic receptors on intact human lymphocytes. Properties and subclass characterization, 1451
Berlin H. *See* Calev A
Berman KF. Cortical "stress tests" in schizophrenia: Regional cerebral blood flow studies, 1304
Bernstein AS, Riedel JA. Psychophysiological response patterns in college students with high physical anhedonia: Scores seem to reflect schizotypy rather than depression, 829
Berrettini WH. *See* Gershon ES
Berrettini WH. *See* Sapin LR
Berrettini WH. *See* Uhde TW
Berrettini WH, Bardakjian J, Cappellari CB, Barnett AL Jr, Albright A, Nurnberger JI Jr, Gershon ES. Skin fibroblast beta-adrenergic receptor function in manic-depressive illness, 1439
Berry S. *See* Baker N
Bertish T. *See* Hamburger-Bar R
Bessler H, Eviatar J, Meshulam M, Tyano S, Djaldetti M, Sirota P. Theophylline-sensitive T-lymphocyte subpopulation in schizophrenic patients, 1025
Biederman J, Keller M, Lavori P, Harmatz J, Knee D, Dubey D, Yunis E. HLA haplotype A26-B38 in affective disorders: Lack of association, 221
Bigelow LB. *See* Casanova MF
Binder RL, Kazamatsuri H, Nishimura T, McNiel DE. Smoking and tardive dyskinesia, 1280
Black DW. *See* Winokur G
Blackwood DHR. *See* St. Clair DM
Blass JP. *See* Gibson GE
Bokan JA. *See* Raskind MA
Bornstein P. *See* Moriearty PL
Bossert S. *See* Berger M
Bossert S. *See* Krieg J-C
Boucher M. *See* Dewan MJ
Bouckoms AJ. *See* Ballantine HT
Boulenger J-P. *See* Uhde TW
Bowers MB Jr. *See* Mazure CM
Boyce P, Kennaway DJ. Effects of light on melatonin production, 473
Bracha HS. Asymmetric rotational (circling) behavior, a dopamine-related asymmetry: Preliminary findings in unmedicated and never-medicated schizophrenic patients, 995
Brecher M, Porjesz B, Begleiter H. Late positive component amplitude in schizophrenics and alcoholics in two different paradigms, 848
Brenner RP. *See* Julius SC
Bridge S. *See* Maguire KP
Bridge TP, Kleinman JE, Soldo BJ, Karoum F. Central catecholamines, cognitive impairment, and affective state in elderly schizophrenics and controls, 139
Bridges M. *See* Pohl R
Brizer D. *See* Crowner ML
Brody D. *See* Peabody CA
Brown SL. *See* van Praag HM
Buchsbaum MS. *See* Post RM
Buchsbaum MS, Wu JC, DeLisi LE, Holcomb HH, Hazlett E, Cooper-Langston K, Kessler R. Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: Differences between normal controls and schizophrenic patients, 479
Buckman TD, Kling AS, Eiduson S, Sutphin MS, Steinberg A. Glutathione peroxidase and CT scan abnormalities in schizophrenia, 1349
Bush D, Rothke S. Long-term outcome of neuroleptic malignant syndrome, 239-le

Cabranes JA. *See* Ayuso-Gutiérrez JL
Calev A, Berlin H, Lerer B. Remote and recent memory in long-hospitalized chronic schizophrenics, 79
Calev A, Korin Y, Kugelmass S, Lerer B. Performance of chronic schizophrenics on matched word and design recall tasks, 699
Callaway E III. Two modest proposals, 665-ed
Camposano S. *See* Lolas F
Capellari CB. *See* Berrettini WH
Carey RJ. Conditioning and the delayed onset of a haloperidol-induced behavioral effect, 269
Carlini EA. *See* Frochtengarten ML
Carson SW, Halbreich U. Effect of treatment on plasma cortisol and dexamethasone, 213
Casacchia M. *See* Rossi A
Casanova MF, Stevens JR, Bigelow LB. Gliosis in schizophrenia, 1172-le
Casas M. *See* Sarrias MJ
Casey DE. *See* Hoffman WF
Caterson I. *See* Johnson GF
Cerfontaine J-L. *See* Demey-Ponsart E
Chang I. *See* Georgotas A
Chang W-H, Chen T-Y, Lee C-F, Hu W-F, Yeh E-K. Low plasma reduced haloperidol/haloperidol ratios in Chinese patients, 1406

Chang W-H, Wu H-S, Tseng Y-T. Reduced haloperidol and haloperidol effects on homovanillic acid in caudate and prefrontal cortex, 1369
Chen T-Y. *See* Chang W-H
Chess S. Lauretta Bender, 1040
Coble P. *See* Jarrett DB
Coccaro EF. *See* Kanof PD
Coffee CE, Hinkle PE, Weiner RD, Nemeroff CB, Krishnan KRR, Varia I, Sullivan DC. Electroconvulsive therapy of depression on patients with white matter hyperintensity, 629
Coffee CE, Weiner RD, Hinkle PE, Cress M, Daughtry G, Wilson WH. Augmentation of ECT seizures with caffeine, 637
Cohen BM. *See* Zubenko GS
Cohen DJ. *See* Minderaa RB
Cohen R. *See* Post RM
Cohen-Cole SA. *See* Kitchin W
Collin C. *See* Lolas F
Colter N. *See* Roberts GW
Connelly P. *See* Naylor GJ
Convit A. *See* Crowner ML
Cooper T. *See* Angrist B
Cooper T. *See* Georgotas A
Cooper TB. *See* Stern SL
Cooper-Langston K. *See* Buchsbaum MS
Coppola R. *See* Keller CH
Corwin J. *See* Angrist B
Courtney N. *See* Raskind MA
Cowdry R. *See* Kellner CH
Cowley DS. *See* Dager SR
Cress M. *See* Coffee CE
Crinella CM. *See* Sandman CA
Crnic L. *See* Reite M
Crow TJ. *See* Roberts GW
Crowner ML, Jaeger J, Convit A, Brizer D, Volavka J. Minor physical anomalies in violent adult inpatients, 1166
Csernansky JG. *See* Whiteford HA

Dager SR, Cowley DS, Dunner DL. Biological markers in panic states: Lactate-induced panic and mitral valve prolapse, 339
Dartigues J-F. *See* Abalan F
Dash RJ. *See* Joseph S
Daughtry G. *See* Coffee CE
Davidson JRT. *See* Krishnan KRR
Davidson M. *See* Hollander E
Davidson M, Mohs RC, Hollander E, Zemlishlany Z, Powchik P, Ryan T, Davis KL. Lecithin and piracetam in Alzheimer's disease, 112-le
Davidson RK. *See* Dilsaver SC
Davis BM. *See* Hollander E
Davis CM. *See* Edlund MJ
Davis KL. *See* Davidson M
Davis KL. *See* Hollander E
Davis KL. *See* Kanof PD
De Belleroche J. *See* Reveley MA
Decina P. *See* Devanand DP
Decina P. *See* Sackheim HA
Deicken RF. Combined alprazolam and phenelzine treatment of refractory depression with panic attacks, 762
De Lisi LE. *See* Buchsbaum MS
DeLisi LE. *See* Gershon ES
De Lisi LE. *See* Post RM
DeLisi LE, Goldin LR, Nurnberger JI, Simmons-Alling S, Hamovit J, Dingman CW. Failure to alleviate symptoms of schizophrenia with the novel use of an antiviral agent, acyclovir (Zovirax), 216
Demey-Ponsart E, Ansseau M, Sulon J, von Frenckell R, Cerfontaine J-L, Papart P, Franck G, Geneen V, Legros J-J. Diagnostic performance of basal free cortisol/18-hydroxy-11-deoxycorticosterone (18-OH-DOC) ratio in endogenous depression: Comparison with the Dexamethasone Suppression Test, 947
De Ruyter M. *See* Maes MHJ
Deutsch SI, Milstoc M, Platovsky G, Wolsky BB, Perry R, Green WH. Cholinesterase activities in blood in infantile autism, 234
Devanand DP, Decina P, Sackheim HA, Hopkins N, Novacenko H, Malitz S. Serial Dexamethasone Suppression Tests in initial suppressors and nonsuppressors treated with electroconvulsive therapy, 463
Dewan MJ, Haldipur CV, Lane E, Donnelly MP, Boucher M, Major LF. Normal cerebral asymmetry in bipolar patients, 1058
de Weert D. *See* D'haenen H.
D'haenen H, de Weert D, Ansseau M. Lack of effects of hospitalization and oral contraceptives on DST results in control subjects, 1499
Dhar AK. *See* Young RC
Dickens P. *See* St. Clair DM
Dickerson PC. *See* Malcolm R
Dilsaver SC, Alessi NE. Chronic inescapable footshock produces cholinergic system supersensitivity, 914
Dilsaver SC, Davidson RK. Cold stress and cholinergic supersensitivity, 1051-le

Dilsaver SC, Majchrzak MJ. Decrease in core temperature as an indication of cholinergic overdrive during amitriptyline withdrawal, 1485
Dilsaver SC, Snider RM, Alessi NE. Amitriptyline supersensitizes a central cholinergic mechanism, 495
Dingman CW. *See* DeLisi LE
Dirlich G. *See* Berger M
Dixon KM. *See* Levy AB
Djaldetti M. *See* Bessler H
Domino EF. NMR chemistry of red blood cell constituents, 396-le
Donald RA. *See* Joyce PR
Donnelly JF. *See* Sandman CA
Donnelly MP. See Dewan MJ
Dorsa DM. *See* Raskind MA
Doty FL. *See* Amsterdam JD
Dougher MJ. *See* Otto MW
Douglass AB, Toogood RW. Temperature regulation and dopamine in schizophrenia, 1048–le
Dube S. *See* Keshavan M
Dubey D. *See* Biederman J
Dunner DL. *See* Dager SR

Edlund MJ, Swann AC, Davis CM. Plasma MHPG in untreated panic disorder, 1491
Ehlers CL, Kupfer DJ. Hypothalamic peptide modulation of EEG sleep in depression: A further application of the S-process hypothesis, 513
Eiduson S. *See* Buckman TD
Eiser AS. *See* Kumar A
Ellinwood EH. *See* Krishnan R
El-Shazly MAM. Prolactin response to TRH in Alzheimer's disease, 661-le
Emrich HM. *See* Herholz K
Erb A. *See* Lesch K-P
Etcheberrigaray R. *See* Lolas F
Ettedgui E. *See* Pohl R
Ettmeier W. *See* Berger M
Evans K. *See* Robertson M
Eviatar J. *See* Bessler H

Fariss BL. *See* Lampe TH
Fauman MA. The relation of dominant and submissive behavior to the humoral immune response in BALB/c mice, 776
Fedorka IB. *See* Jarrett DB
Feinberg M. *See* Kumar A
Feldman M. *See* Petty F
Feldman SR, Krishnan KRR, McPherson H, Meglin DE. Organic affective disorder in a patient with congenital adrenal hyperplasia, 767
Fernstrom MH, Krowinski RL, Kupfer DJ. Appetite and food preference in depression: Effects of imipramine treatment, 529
Fiducia D. *See* Wade JB
Fieve RR. *See* Goodnick PJ
Fischer C. *See* Rogeness GA
Flegel P. *See* Grunhaus L
Flegel P. *See* Kumar A
Fleischhacker WW, Barnas C, Ledochowski M. Hyponatremia-induced organic mental disorder may mask paranoid schizophrenia, 650
Franck G. *See* Demey-Ponsart E
Franks RD. *See* Baker N
Freedman R. *See* Baker N
Frick K. *See* Gaebel W
Fritze J, Beckmann H. Erythrocyte acetylcholinesterase in psychiatric disorders and controls, 1097
Frochtengarten ML, Villares JCB, Maluf E, Carlini EA. Depressive symptoms and the Dexamethasone Suppression Test in parkinsonian patients, 386
Fulton CL. *See* Giles DE
Fuwano S. *See* Itoh N

Gaebel W, Ulrich G, Frick K. Visuomotor performance of schizophrenic patients and normal controls in a picture viewing task, 1227
Gallucci M. *See* Rossi A
Galzin AM. *See* Poirier MF
Ganguli R. *See* Kelly RH
Gannon M. *See* Mitchell JE
Garcia-Camba E. *See* Ayuso-Gutiérrez JL
Gardner D. *See* Kellner CH
Garver DL. *See* Sautter F
Gattaz WF, Köllisch M, Thuren T, Virtanen JA, Kinnunen PKJ. Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy, 421
Gelpí E. *See* Sarrias MJ
Geneen V. *See* Demey-Ponsart E
Georgotas A, McCue RE, Cooper T, Chang I, Mir P, Welkowitz J. Clinical predictors of response to antidepressants in elderly patients, 733
Gershon ES. *See* Berrettini WH

Gershon ES, Merril CR, Goldin LR, DeLisi LE, Berrettini WH, Nurnberger JI Jr. The role of molecular genetics in psychiatry, 1388
Gibson GE, Nielsen P, Sherman KA, Blass JP. Diminished mitogen-induced calcium uptake by lymphocytes from Alzheimer patients, 1079
Giles DE, Roffwarg HP, Rush AJ. REM latency concordance in depressed family members, 910
Giles DE, Schlesser MA, Rush AJ, Orsulak PJ, Fulton CL, Roffwarg HP. Polysomnographic findings and dexamethasone nonsuppression in unipolar depression: A replication and extension, 872
Giriunas IE. *See* Ballantine HT
Goldin LR. *See* DeLisi LE
Goldin LR. *See* Gershon ES
Goldstein S. Treatment of social phobia with clonidine, 369
Gomez-Mont F. *See* Volkow ND
Goodnick PJ, Fieve RR, Schlegel A. Lithium discontinuation, serum cortisol, and 5-HTP, 240-le
Goodwin GM, Wood AJ. Captopril as an antidepressant: Lack of effect in animal models of serotonergic function, 1274
Grabowski J. *See* Keshavan M
Gray F. *See* Misiaszek J
Greden JF. *See* Grunhaus L
Greden JF. *See* Meador-Woodruff JH
Green WH. *See* Deutsch SI
Greenhouse JB. *See* Jarrett DB
Grochocinski V. *See* Hudson JI
Grunhaus L. *See* Kumar A
Grunhaus L. *See* Meador-Woodruff JH
Grunhaus L, Flegel P, Haskett RF, Greden JF. Serial Dexamethasone Suppression Tests in simultaneous panic and depressive disorders, 332
Grunhaus L, Tiongco D, Haskett RF, Greden JF. The Dexamethasone Suppression Test in patients with panic disorder or agoraphobia with panic attacks, 517
Grunhaus LJ. Dosage, threshold, and duration of ECT, 1293-le
Gurguis G. *See* Meador-Woodruff JH

Häggendal J. *See* Almay BGL
Halbreich U. *See* Carson SW
Haldipur CV. *See* Dewan MJ
Halmi KA. *See* Newman MM
Hamburger-Bar R, Kindler S, Bertish T, Lerer B. Conditioned avoidance acquisition and extinction following repeated electroconvulsive shock: Strain effect and response to vasopressin, 593
Hamovit J. *See* DeLisi LE
Harmatz J. *See* Biederman J
Haskett RF. *See* Grunhaus L
Haskett RF. *See* Kumar A
Haskett RF. *See* Meador-Woodruff JH
Hatsukami D. *See* Mitchell JE
Hayes LR. *See* McAllister TW
Hazlett E. *See* Buchsbaum MS
Heiss W-D. *See* Herholz K
Herholz K, Krieg JC, Emrich HM, Pawlik G, Beil C, Pirke KM, Pahl JJ, Wagner R, Wienhard K, Ploog D, Heiss W-D. Regional cerebral glucose metabolism in anorexia nervosa measured by positron emission tomography, 43
Hermann BP, Wyler AR, Richey ET. Epilepsy, frontal lobe, and personality, 1055-ed
Herrick. *See* Moriearty PL
Hinkle PE. *See* Coffee CE
Hirsch SR. *See* Reveley MA
Hirschowitz J. *See* Sautter F
Hoffman F Jr. *See* Mazure CM
Hoffman WF, Labs SM, Casey DE. Neuroleptic-induced parkinsonism in older schizophrenics, 427
Holcomb HH. *See* Buchsbaum MS
Holcomb HH. *See* Post RM
Hollander E. *See* Davidson M
Hollander E, Davidson M, Mohs RC, Horvath TB, Davis BM, Zemishlany Z, Davis KL. RS 86 in the treatment of Alzheimer's disease: Cognitive and biological effects, 1067
Holsboer F. *See* Wiedemann K
Holsboer F, von Bardeleben U, Wiedemann K, Müller OA, Stalla GK. Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression, 228
Hood L. *See* Krishnan R
Hopkins N. *See* Devanand DP
Horrobin DF. *See* Virkkunen ME
Horvath TB. *See* Hollander E
Hovermale LS. *See* Vieweg WVR
Hu W-H. *See* Chang W-H
Hudson JI, Pope HG, Jonas JM, Stakes JW, Grochocinski V, Lipinski JF, Kupfer DJ. Sleep EEG in bulimia, 820
Hunt G. *See* Johnson GF

Hunt NJ. Hypoglycemic effect of lithium, 798-le
Hyrman V. Dosage, threshold, and duration of ECT, 1294–le

Inamdar S. *See* Volkow ND
Insel TR. *See* Zohar J
Insel TR, Hill JL. Infant separation distress in genetically fearful rats, 786
Isseroff RG, Stoler M, Ophir D, Lancet D, Sirota P. Olfactory sensitivity to androstenone in schizophrenic patients, 922
Itoh N, Matsui N, Fuwano S, Yaginuma H, Miyashita O, Sakai M. Serial DST, TRH test, and TRH-like immunoreactivity measurements in major affective disorders, 559
Izumiya Y. *See* Kiriike N

Jacobs SC, Mason J, Kosten TR, Kasl SV, Ostfeld AM, Wahby V. Urinary free cortisol and separation anxiety early in the course of bereavement and threatened loss, 148
Jacobsen FM, Dreizzen A, Wehr TA. Diurnal mood variation and REM latency in depression, 800-le, 1045-le
Jaeckel RS. *See* Kathol RG
Jaeckle RS. *See* Lopez JF
Jankowski W. *See* Pohl R
Jarrett DB, Miewald JM, Fedorka IB, Coble P, Kupfer DJ, Greenhouse JB. Prolactin secretion during sleep: A comparison between depressed patients and healthy control subjects, 1216
Javors MA. *See* Rogeness GA
Jenkins DK. *See* Virkkunen ME
Jimerson D. *See* Pohl R
Joffe RT, Singer W. Effect of phenelzine on thyroid function in depressed patients, 1033
Joffe RT, Swinson RP. Carbamazepine in obsessive-compulsive disorder, 1169
Joffe RT, Uhde TW, Post RM, Minichiello MD. Motor activity in depressed patients treated with carbamazepine, 941
John R. *See* Volkow ND
Johns CA. *See* Kanof PD
Johnson GF, Hunt G, Kerr K, Caterson I. The plasma dexamethasone "window" and the Dexamethasone Suppression Test in depression, 1035
Johnson MH. *See* Stern SL
Johnstone EC. *See* Roberts GW
Jonas JM. *See* Hudson JI
Jones BA. *See* Stern SL
Jones DA. *See* Keshavan M
Jones J. *See* Reite M
Joseph NE, Renshaw PF, Leigh JS Jr. Systemic lithium administration alters rat cerebral cortex phospholipids, 540
Joseph S, Kulhara P, Dash RJ. Dexamethasone Suppression Test in schizophrenic patients: Report from India, 792
Joshi M. *See* Wilkinson M
Joyce PR, Donald RA, Livesey JH, Abbott RM. The prolactin response to metoclopramide is increased in depression and in euthymic rapid cycling bipolar patients, 508
Julius SC, Brenner RP. Myoclonic seizures with lithium, 1184

Kaemingk K. *See* Reite M
Kahn R. *See* van Praag HM
Kanof PD, Coccaro EF, Johns CA, Siever LJ, Davis KL. Platelet [$^3$H]imipramine binding in psychiatric disorders, 278
Karoum F. *See* Bridge TP
Karoum F. *See* Syzmanski HV
Kasl SV. *See* Jacobs SC
Kasprisin A. *See* Wade JB
Katahara S. *See* Kiriike N
Kathol RG. *See* Lopez JF
Kathol RG, Meller W, Jaeckle RS, Lopez JF. Stable adrenocorticotropin-stimulated 11-β-hydroxylase activity but loss of age-related changes in patients with hypercortisolemia, 1243
Kawakita Y. *See* Kiriike N
Kazamatsuri H. *See* Binder RL
Keller M. *See* Biederman J
Kellner CH, Post RM, Putnam F, Cowdry R, Gardner D, Kling MA, Minichiello MD, Trettau JR, Coppola R. Intravenous procaine as a probe of limbic system activity in psychiatric patients and normal controls, 1107
Kelly RH, Ganguli R, Rabin BS. Antibody to discrete areas of the brain in normal individuals and patients with schizophrenia, 1488
Kennaway DJ. *See* Boyce P
Kerr K. *See* Johnson GF
Keshavan M, Jones DA, Dube S, Grabowski J, Bell J, Sitaram N. Cardioacceleratory responses to arecoline infusion during sleep in depressive, anxious, and normal subjects, 1473
Kessler R. *See* Buchsbaum MS
Kindler S. *See* Hamburger-Bar R

Kinney DK. *See* Woods BT
Kinnunen PKJ. *See* Gattaz WF
Kiriike N, Maeda Y, Nishiwaki S, Izumiya Y, Katahara S, Mui K, Kawakita Y, Nishikimi T, Takeuchi K, Takeda T. Iatrogenic torsade de pointes induced by thioridazine, 99
Kiriike N, Nishiwaki S, Izumiya Y, Maeda Y, Kawakita Y. Thyrotropin, prolactin, and growth hormone responses to tryrotropin-releasing hormone in anorexia nervosa and bulimia, 167
Kitchin W, Cohen-Cole SA, Mickel SF. Adrenoleukodystrophy: Frequency of presentation as a psychiatric disorder, 1375
Kleinman JE. *See* Bridge TP
Kling AS. *See* Buckman TD
Kling MA. *See* Kellner CH
Knee D. *See* Biederman J
Knott VJ, Lapierre YD. Electrophysiological and behavioral correlates of psychomotor responsivity in depression, 313
Koenigsberg HW, Pollack C, Sullivan T. The sleep lactate infusion: Arousal and the panic mechanism, 789
Koga A. *See* Nishikawa T
Köllisch M. *See* Gattaz WF
Kopin I. *See* Pohl R
Korin Y. *See* Calev A
Korpassy A. *See* Yassa R
Kosten TR. *See* Jacobs SC
Kraemer HC. *See* Whiteford HA
Kramer G. *See* Petty F
Kretzschmar K. *See* Schlegel S
Krieg J-C. *See* Berger M
Krieg J-C. *See* Herholz K
Krieg J-C, Bossert S, Pirke K-M, von Zerssen D, Berger M. The influence of the muscarinic agonist RS 86 on the cortisol system, 573
Kripke DF. *See* Ancoli-Israel S
Kripke DF. Ultradian sleep rhythms and cortisol, 928-le
Krishnan KRR. *See* Coffee CE
Krishnan KRR. *See* Feldman SR
Krishnan KRR, Davidson JRT, Rayasam K, Tanas KS, Shope FS, Pelton S. Diagnostic utility of the Dexamethasone Suppression Test, 618
Krishnan R, Ellinwood EH Jr, Laszlo J, Hood L, Ritchie J. Effect of gamma interferon on the hypothalamic-pituitary-adrenal system, 1163
Krowinski RL. *See* Fernstrom MH
Kugelmass S. *See* Calev A
Kulhara P. *See* Joseph S
Kumar A, Shipley JE, Eiser AS, Feinberg M, Flegel P, Grunhaus L, Haskett RF. Clinical correlates of sleep onset REM periods in depression, 1477
Kupfer DJ. *See* Ehlers A
Kupfer DJ. *See* Fernstrom MH
Kupfer DJ. *See* Hudson JI
Kupfer DJ. *See* Jarrett DB
Kurachi M. *See* Minabe Y
Kutt H. *See* Young RC

Labs SM. *See* Hoffman WF
Lal S. *See* Yassa R
Lamella M. *See* Volkow ND
Lampe TH, Fariss BL, Risse SC, Raskind MA, Plymate SR. Laboratory evaluation for Cushing's syndrome in psychiatric patients with cortisol nonsuppression following the overnight Dexamethasone Suppression Test, 1264
Lancet D. *See* Isseroff RG
Lander M. *See* Manji HK
Lane E. *See* Dewan MJ
Langer SZ. *See* Poirier MF
Lapierre YD. *See* Knott VJ
Lascelles P. *See* Robertson M
Laszlo J. *See* Krishnan R
Laudenslager M. *See* Reite M
Lauer C. *See* Wiegand M
Laux G. *See* Lesch K-P
Lavori P. *See* Biederman J
Ledochowski M. *See* Fleischhacker WW
Lee C-F. *See* Chang W-H
Lee KL. *See* Lifschitz K
Legros J-J. *See* Demey-Ponsart E
Leigh JS Jr. *See* Joseph NE
Lemus C. *See* van Praag HM
Lerer B. *See* Calev A
Lerer B. *See* Hamburger-Bar R
Lesch K-P, Laux G, Erb A, Pfüller H, Beckman H. Attenuated growth hormone response to growth hormone-releasing hormone in major depressive disorder, 1495
Levine AS. *See* Mitchell JE
Levinson DF, Simpson G. Sequelae of neuroleptic malignant syndrome, 237-le
Levy AB, Dixon KN. DST in bulimia without endogenous depression, 783
Lifschitz K, Lee KL, O'Keefe RT. Event-related EEG field changes in aroused subjects and schizophrenic patients, 440
Lipinski JF. *See* Hudson JI

Livesey JH. *See* Joyce PR
Lofthouse R. *See* Roberts GW
Lolas F, Collin C, Camposano S, Etcheberrigaray R, Rees R. Asymmetry of augmenting/reducing in visual and auditory evoked potentials, 1413
Loo H. *See* Poirier MF
Lopez JF. *See* Kathol RG
Lopez JF, Kathol RG, Jaeckle RS, Meller W. The HPA axis response to insulin hypoglycemia in depression, 153
Lowry MT, Meltzer HY. Dexamethasone bioavailability: Implications for DST research, 373
Lucignani G. *See* Porrino LJ
Lycaki H. *See* Pohl R

Maas JW. *See* Rogeness GA
Macedo CA. *See* Rogeness GA
Maeda Y. *See* Kiriike N
Maes MHJ, De Ruyter M, Suy E. Prediction of subtype and severity of depression by means of Dexamethasone Suppression Test, L-tryptophan : competing amino acid ratio, and MHPG flow, 177
Maguire KP, Schweitzer I, Biddle N, Bridge S, Tiller JWG. The Dexamethasone Suppression Test: Importance of dexamethasone concentrations, 957
Majchrzak MJ. *See* Dilsaver SC
Major LF. *See* Dewan MJ
Malcolm R, O'Neil PM, Von JM, Dickerson PC. Naltrexone and dysphoria: A double-blind placebo controlled trial, 710
Malinakova I. *See* Zubenko GS
Malitz S. *See* Devanand DP
Malitz S. *See* Sackeim HA
Maluf E. *See* Frochtengarten ML
Mamelak M. *See* Williamson P
Manciet G. *See* Abalan F
Manji HK, Lander M. Bromocriptine in neuroleptic resistance, 523-le
Manku MS. *See* Virkkunen ME
Marchi P. *See* Newman MM
Martínez E. *See* Sarrias MJ
Mason J. *See* Jacobs SC
Mason W. *See* Ancoli-Israel S
Mathew RJ, Wilson WH. Elevated hematocrit in patients with schizophrenia, 907
Matsui N. *See* Itoh N
Mazure CM, Bowers MB Jr, Hoffman F Jr, Miller KB, Nelson JC. Plasma catecholamine metabolites in subtypes of major depression, 1469
McAllister TW, Hayes LR. TRH test, DST, and response to desipramine in primary degenerative dementia, 189
McCue RE. *See* Georgotas A
McGinn T. *See* Schwartz BD
McKeag DW. *See* Pettegrew JW
McNiel DE. *See* Binder RL
McPherson H. *See* Feldman SR
Meador-Woodruff JH, Gurguis G, Grunhaus L, Haskett RF, Greden JF. Multiple depressive episodes and plasma postdexamethasone cortisol levels, 583
Meador-Woodruff JH, Haskett RF, Grunhaus L, Akil H, Watson SJ, Greden JF. Postdexamethasone plasma cortisol and β-endorphin levels in depression: Relationship to severity of illness, 1137
Meglin DE. *See* Feldman SR
Meller W. *See* Kathol RG
Meller W. *See* Lopez JF
Meltzer HY. *See* Lowry MT
Merril CR. *See* Gershon ES
Meshulam M. *See* Bessler H
Mickel SF. *See* Kitchin W
Miewald JM. *See* Jarrett DB
Miller KB. *See* Mazure CM
Miller KB, Nelson JC. Dexamethasone nonsuppression and EEG abnormalities, 1151
Milstoc M. *See* Deutsch SI
Minabe Y, Tanii Y, Kurachi M. Acute effect of some psychotropic drugs on low-frequency amygdaloid kindled seizures, 1444
Minderaa RB, Anderson GM, Volkmar FR, Akkerhuis GW, Cohen DJ. Urinary 5-hydroxyinodoleacetic acid and whole blood serotonin and tryptophan in autistic and normal subjects, 933
Minichiello MD. *See* Joffe RT
Minichiello MD. *See* Kellner CH
Minshew NJ. *See* Pettegrew JW
Mir P. *See* Georgotas A
Misiaszek J, Gray F, Yates A. The calming effects of negative air ions on manic patients: A pilot study, 107
Mitchell JE, Morley JE, Levine AS, Hatsukami D, Gannon M, Pfohl D. High-dose naltrexone therapy and dietary counseling for obesity, 35
Miyashita O. *See* Itoh N

Modai I, Schwartz B, Aizenberg D. Serum pseudocholinesterase in psychiatric patients, 1238
Mohs RC. *See* Davidson M
Mohs RC. *See* Hollander E
Moises HW. *See* Bering B
Mol JFA. *See* van den Bosch RJ
Moriearty PL, Herrick C, Shafey M, Bornstein P, Becker RE. Platelet MAO-B and endogenous MAO-A inhibitory activity in depressed patients: Stability with electroconvulsive treatment, 1155
Morley JE. *See* Mitchell JE
Muckle A. *See* Baker N
Mui K. *See* Kiriike N
Müller OA. *See* Holsboer F
Müller WE. *See* Bering B
Munjack D. *See* Schneider LS
Murburg MM. *See* Raskind MA

Nagamoto H. *See* Baker N
Nasrallah A. *See* Winokur G
Naylor EW. *See* Syzmanski HV
Naylor GJ, Smith AHW, Connelly P. A controlled trial of methylene blue in severe depressive illness, 657
Neeley P. *See* Sackeim HA
Nelson HD. *See* Barkai AI
Nelson JC. *See* Mazure CM
Nelson JC. *See* Miller KB
Nelson LD. *See* Stern SL
Nemeroff CB. *See* Coffee CE
Newman MM, Halmi KA, Marchi P. Relationship of clinical factors to caloric requirements in subtypes of eating disorders, 1253
Nielsen P. *See* Gibson GE
Nimgaonkar VL. β-adrenergic agonists and 5-HT receptors, 929-le
Nishikawa T, Tanaka M, Tsuda A, Koga I, Uchida Y. Ceruletide for tardive dyskinesia, 797-le
Nishikimi T. *See* Kiriike N
Nishimura T. *See* Binder RL
Nishiwaki S. *See* Kiriike N
Novacenko H. *See* Devanand DP
Nurnberger JI Jr. *See* Berrettini WH
Nurnberger JI Jr. *See* DeLisi LE
Nurnberger JI Jr. *See* Gershon ES
Nurnberger JI Jr. *See* Sapin LR

O'Keefe RT. *See* Lifshitz K
Oliver CJ. *See* St. Clair DM
O'Neil PM. *See* Malcolm R
Ophir D. *See* Isseroff RG
Oreland L. *See* Almay BGL
Orr SP, Pitman RK. Electrodermal psychophysiology of anxiety disorder: Orienting response and spontaneous fluctuations, 653
Orsulak PJ. *See* Giles DE
Ortiz A. *See* Pohl R
Ortiz A. *See* Yeragani VK
Ostfeld AM. *See* Jacobs SC
Otto MW, Yeo RA, Dougher MJ. Right hemisphere involvement in depression: Toward a neurophysiological theory of negative affective experiences, 1201

Pahl JJ. *See* Herholz K
Palmer R. *See* Schneider LS
Papart P. *See* Demey-Ponsart E
Passariello R. *See* Rossi A
Pawlik G. *See* Herholz K
Peabody CA. *See* Whiteford HA
Peabody CA, Brody D, Warner MD. Tardive dyskinesia after low-dose haloperidol, 111-le
Pelton S. *See* Krishnan KRR
Perry R. *See* Deutsch SI
Pettegrew JW, Short JW, Woessner RD, Strychor S, McKeag DW, Armstrong J, Minshew NJ, Rush AJ. The effect of lithium on the membrane molecular dynamics of normal human erythrocytes, 857
Petty F, Kramer G, Feldman M. Is plasma GABA of peripheral origin? 725
Pfeiffer CC. Elementary, dear Watson! 805-ed
Pfohl D. *See* Mitchell JE
Pfüller H. *See* Lesch K-P
Pimoule C. *See* Poirier MF
Pirke KM. *See* Herholz K
Pirke KM. *See* Krieg J-C
Pitman RK. *See* Orr SP
Platovsky G. *See* Deutsch SI
Ploog D. *See* Herholz K
Plymate SR. *See* Lampe TH
Pohl R. *See* Yeragani VK
Pohl R, Ettedgui E, Bridges M, Lycaki H, Jimerson D, Kopin I, Rainey JM. Plasma MHPG levels in lactate and isoproterenol anxiety states, 1127
Pohl R, Rainey JM, Ortiz A, Yeragani VK. Locus coerulus and anxiety, 116-le
Pohl R, Yeragani VK, Balon R, Jankowski W. Maybe handwriting would help, 1504-le

Poirier MF, Galzin AM, Loo H, Pimoule C, Segonzac A, Benkelfat C, Sechter D, Zarifan E, Schoemaker H, Langer SZ. Changes in [$^3$H]5-HT uptake and [$^3$H]imipramine binding in platelets after chlorimipramine in healthy volunteers, 287
Pollack C. *See* Koenigsberg HW
Pollack MH, Rosebaum JF. Verapamil in the treatment of recurrent unipolar depression, 779
Pope HG. *See* Hudson JI
Porjesz B. *See* Brecher M
Porrino LJ, Lucignani G. Different patterns of local brain energy metabolism associated with high and low doses of methylphenidate. Relevance to its action in hyperactive children, 126
Portnoy S. *See* Sackeim HA
Post RM. *See* Joffe RT
Post RM. *See* Kellner CH
Post RM. *See* Uhde TW
Post RM, DeLisi LE, Holcomb HH, Uhde TW, Cohen R, Buchsbaum MS. Glucose utilization in the temporal cortex of affectively ill patients: Positron emission tomography, 545
Powchik P. *See* Davidson M
Princep L. *See* Volkow ND
Putnam F. *See* Kellner CH

Rabin BS. *See* Kelly RH
Rainey JM. *See* Pohl R
Rainey JM. *See* Yeragani VK
Raskind MA. *See* Lampe TH
Raskind MA, Courtney N, Murburg MM, Backus FI, Bokan JA, Ries RK, Dorsa DM, Weitzman RE. Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients, 453
Rayasam K. *See* Krishnan KRR
Recordati A. *See* Reveley MA
Rees R. *See* Lolas F
Reite M, Laudenslager M, Jones J, Crnic L, Kaemingk K. Interferon decreases REM latency, 104
Renshaw PF. *See* Joseph NE
Renshaw PF. A diffusional contribution to lithium isotope effects, 73
Renshaw PF. Lithium, metal ions, and choline, 660-le
Reveley MA, De Belleroche J, Recordati A, Hirsch SR. Increased CSF amino acids and ventricular enlargement in schizophrenia: A preliminary study, 413
Richey ET. *See* Hermann BP
Riedel JA. *See* Bernstein AS
Ries RK. *See* Raskind MA
Rihmer Z. The geography of DST, 1044-le
Risse SC. *See* Lampe TH
Ritchie J. *See* Krishnan R
Roberts GW, Colter N, Lofthouse R, Johnstone EC, Crow TJ. Is there gliosis in schizophrenia? Investigation of the temporal lobe, 1459
Robertson M, Evans K, Robinson A, Trimble M, Lascelles P. Abnormalities of copper in Gilles de la Tourette syndrome, 968
Robinson A. *See* Robertson M
Roffwarg HP. *See* Giles DE
Rogeness GA, Javors MA, Maas JW, Macedo CA, Fischer C. Plasma dopamine-β-hydroxylase, HVA, MHPG, and conduct disorder in emotionally disturbed boys, 1158
Rosenbaum JF. *See* Pollack MH
Rosenberg S. *See* Wade JB
Rossi A, Stratta P, Casacchia M, Gallucci M, Passariello R. Corpus callosum in schizophrenia, 1043-le
Roth SD. *See* Addonizio G
Rothblat LA. *See* Sapin LR
Rothke S. *See* Bush D
Rowe WT. *See* Vieweg WVR
Roy-Byrne PP. *See* Uhde TW
Rozendaal N. *See* van den Bosch RJ
Rush AJ. *See* Giles DE
Rush AJ. *See* Pettegrew JW
Ryan T. *See* Davidson M

Sackeim HA. *See* Devanand DP
Sackeim HA, Decina P, Portnoy S, Neeley P, Malitz S. Studies of dosage, seizure threshold, and seizure duration in ECT, 249
Sakai M. *See* Itoh N
Sandman CA, Barron J, Crinella FM, Donnelly JF. Influence of naloxone on brain and behavior of a self-injurious woman, 899
Sapin LR, Berrettini WH, Nurnberger JI Jr, Rothblat LA. Mediational factors underlying cognitive changes and laterality in affective illness, 979
Sarrias MJ, Artigas F, Martínez E, Gelpí E, Alvarez E, Udina C, Casas M. Decreased plasma serotonin in melancholic patients: A study with clomipramine, 1429
Sautter F, Garver DL, Zemlan FP, Hirschowitz J. Growth hormone response to apomorphine and family patterns of illness, 717

Schlegel A. *See* Goodnick PJ
Schlegel S, Kretzschmar K. Computed tomography in affective disorders. Part I. Ventricular and sulcal measurements, 4
Schlegel S, Kretzschmar K. Computed tomography in affective disorders. Part II. Brain density, 15
Schlesser MA. *See* Giles DE
Schneider LS, Munjack D, Severson JA, Palmer R. Platelet [$^3$H] imipramine binding in generalized anxiety disorder, panic disorder, and agoraphobia with panic attacks, 59
Schoemaker H. *See* Poirier MF
Schreiber G, Belmaker RH. In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol, 1417
Schreiber W. *See* Berger M
Schulz SC. *See* Zipursky RB
Schwartz B. *See* Modai I
Schwartz BD, McGinn T, Winstead DK. Disordered spatiotemporal processing in schizophrenics, 688
Schweitzer I. *See* Maguire KP
Sechter D. *See* Poirier MF
Seggie J. *See* Wilkinson M
Segonzac A. *See* Poirier MF
Settle RG. *See* Amsterdam JD
Severson JA. *See* Schneider LS
Shafrey M. *See* Moriearty PL
Sherman KA. *See* Gibson GE
Shipley JE. *See* Kumar A
Shope FS. *See* Krishnan KRR
Short JW. *See* Pettegrew JW
Siever LJ. *See* Kanof PD
Simmons-Alling S. *See* DeLisi LE
Simpson G. *See* Levinson DF
Singer W. *See* Joffe RT
Sirota P. *See* Bessler H
Sirota P. *See* Isseroff RG
Sitaram N. *See* Keshavan M
Smeltzer DJ. *See* Stern SL
Smith AHW. *See* Naylor GJ
Smith RC. Confirmation of Babinski-like response in periodic movements in sleep (nocturnal myoclonus), 1271
Snider RM. *See* Dilsaver SC
Soldo BJ. *See* Bridge TP
Stakes JW. *See* Hudson JI
Stalla GK. *See* Holsboer F
St. Clair DM, Blackwood DHR, Oliver CJ, Dickens P. P3 abnormality in fragile X syndrome, 303
Steinberg A. *See* Buckman TD
Stern SL, Cooper TB, Johnson MH, Jones BA, Nelson LD, Smeltzer DJ. Lack of weight gain under desipramine, 796-le
Stevens JR. *See* Casanova MF
Stokes PE. DST update: The hypothalamic-pituitary-adrenocortical axis and affective illness, 245–ed
Stoler M. *See* Isseroff RG
Stratta P. *See* Rossi A
Strychor S. *See* Pettegrew JW
Sullivan DC. *See* Coffee CE
Sullivan T. *See* Koenigsberg HW
Sullivan TB. *See* Zammitt GK
Sulon J. *See* Demey-Ponsart E
Susman VL. *See* Addonizio G
Sutphin MS. *See* Buckman TD
Suy E. *See* Maes MHJ
Swann AC. *See* Edlund MJ
Swinson RP. *See* Joffe RT
Szymanski HV, Naylor EW, Karoum F. Plasma phenylethylamine and phenylalanine in chronic schizophrenic patients, 194

Takeda T. *See* Kiriike N
Takeuchi K. *See* Kiriike N
Tanaka M. *See* Nishikawa T
Tanas KS. *See* Krishnan KRR
Tanii Y. *See* Minabe Y
Taylor MA. *See* Wade JB
Thiemann S. *See* Whiteford HA
Thuren T. *See* Gattaz WF
Thomas EK. *See* Ballantine HT
Tiller JWG. *See* Maguire KP
Tiongco D. *See* Grunhaus L
Toogood RW. *See* Douglass AB
Trettau JR. *See* Kellner CH
Trimble M. *See* Robertson M
Trzepacz PT. *See* Webb M
Trzepacz PT, Webb M. The choreometer: An objective test of chorea during voluntary movements, 771
Tseng Y-T. *See* Chang W-H
Tsuda A. *See* Nishikawa T
Tyano S. *See* Bessler H

Uchida Y. *See* Nishikawa T
Udina C. *See* Sarrias MJ
Uhde TW. *See* Joffe RT
Uhde TW. *See* Post RM

Uhde TW, Berrettini WH, Roy-Byrne PP, Boulanger J-P, Post R. Platelet [$^3$H]imipramine binding in patients with panic disorder, 52
Ulrich G. *See* Gaebel W

van den Bosch RJ, Rozendaal N, Mol JMFA. Symptom correlates of eye tracking dysfunction, 919
van Kammen DP. Columbus, grantsmanship, and clinical research, 1301-ed
van Kammen DP. 5-HT, a neurotransmitter for all seasons? 1-ed
van Kammen DP. 5-HT and the functional approach (response), 1503
van Praag HM. 5-HT and the functional approach, 1503-le
van Praag HM, Kahn R, Asnis GM, Lemus CZ, Brown SL. Therapeutic indications for serotonin-potentiating compounds: A hypothesis, 205
van Praag HM, Lemus C, Kahn R. Hormonal probes of central serotonergic activity: Do they really exist? 86
Varia I. *See* Coffee CE
Vieweg WVR, Yank GR, Rowe WT, Hovermale LS. Diurnal variation of sodium and water metabolism among patients with psychosis, intermittent hyponatremia, and polydipsia (PIP syndrome), 224
Villares JCB. *See* Frochtengarten ML
Virkkunen ME, Horrobin DF, Jenkins DK, Manku MS. Plasma phospholipid essential fatty acids and prostaglandins in alcoholic, habitually violent, and impulsive offenders, 1087
Virtanen JA. *See* Gattaz WF
Volavka J. *See* Crowner ML
Volkmar FR. *See* Minderaa RB
Volkow ND, Gomez-Mont F, Inamdar S, Lamella M, Prichep L, John R. Multivariate analyses of the EEG in normal adolescents, 199
Von JM. *See* Malcolm R
von Bardeleben U. *See* Holsboer F
von Frenckell R. *See* Demey-Ponsart E
von Knorring L. *See* Almay BGL
von Zerssen D. *See* Berger M
von Zerssen D. *See* Krieg J-C
von Zerssen D. *See* Wiegand M

Wade JB, Taylor MA, Kasprisin A, Rosenberg S, Fiducia D. Tardive dyskinesia and cognitive impairment, 393
Wagner R. *See* Herholz K
Wahby V. *See* Jacobs SC
Waldo M. *See* Baker N
Warner MD. *See* Peabody CA
Watson SJ. *See* Meador-Woodruff JH
Weaver LA, Williams RW. ECT: Second generation instruments, 1181-ed
Webb M. *See* Trzepacz PT
Webb M, Trzepacz PT. Huntington's disease: Correlations of mental status with chorea, 751
Weinberg P. *See* Yeragani VK
Weiner RD. *See* Coffee CE
Weitzman RE. *See* Raskind MA
Welkowitz J. *See* Georgotas A
Werstiuk ES. *See* Wilkinson M
Whiteford HA, Peabody C, Thiemann S, Kraemer HC, Csernansky JG, Berger PA. The effect of age on baseline and postdexamethasone cortisol levels in major depressive disorder, 1029
Wiedemann K. *See* Holsboer F
Wiedemann K, Holsboer F. Plasma dexamethasone kinetics during the DST after oral and intravenous administration of the test drug, 1340
Wiegand M, Berger M, Zulley J, Laver C, von Zerssen D. The influence of daytime naps on the therapeutic effect of sleep deprivation, 389
Wienhard K. *See* Herholz K
Wilkinson M, Joshi M, Werstiuk ES, Seggie J. Lithium and rhythms of beta-adrenergic ([$^3$H] CGP-12177) binding in intact rat retina, pineal gland, and hypothalamus, 1191
Williams RW. *See* Weaver LA
Williamson P, Mamelak M. Frontal spectral EEG findings in acutely ill schizophrenics, 1021
Wilson WH. *See* Coffee CE
Wilson WH. *See* Mathew RJ
Winokur A. *See* Amsterdam JD
Winokur G, Black DW, Nasrallah A. DST nonsuppressor status: Relationship to specific aspects of the depressive syndrome, 360
Winstead DK. *See* Schwartz BD
Woessner RD. *See* Pettegrew JW
Wolsky BB. *See* Deutsch SI
Wood AJ. *See* Goodwin GM
Woods BT, Yurgelun-Todd D, Kinney DK. Relationship of neurological abnormalities in schizophrenics to family psychopathology, 325
Wortis J. The history of intelligence, 1425-ed
Wortis J. The irrationals, 401-ed
Wortis J. What is sleep? 931-ed

Wu H-S. *See* Chang W-H
Wu JC. *See* Buchsbaum MS
Wyler AR. *See* Hermann BP

Yaginuma H. *See* Itoh N
Yank GR. See Vieweg WVR
Yassa R, Lal S, Korpassy A, Ally J. Nicotine exposure and tardive dyskinesia, 67
Yates A. *See* Misiaszek J
Yeh E-K. *See* Chang W-H
Yeo RA. *See* Otto MW
Yeragani VK. *See* Pohl R
Yeragani VK, Balon R, Pohl R, Ortiz A, Weinberg P, Rainey JM. Do higher preinfusion heart rates predict laboratory-induced panic attacks? 554
Yosiphovich KI. In search of a common language, 526-ed
Yosiphovich KI. Towards psychiatric détente, 525-ed
Young RC, Alexopoulos GS, Dhar AK, Kutt H. Plasma 10-hydroxynortriptyline and renal function in elderly depressives, 1283
Yunis E. *See* Biederman J
Yurgelun-Todd D. *See* Woods BT

Zammit GK, Sullivan TB. Thioridazine and neuroleptic malignant syndrome, 1296-le
Zarifian E. *See* Poirier MF
Zemishlany Z. *See* Davidson M
Zemishlany Z. *See* Hollander E
Zemlan FP. *See* Sautter F
Zhou D, Shen Y, Shu L, Lo H. Dexamethasone Suppression Test and urinary MHPG · $SO_4$ determination in depressive disorders, 883
Zipursky RB, Schulz SC. Seasonality of birth and CT findings in schizophrenia, 1288
Zohar J, Insel TR. Obsessive-compulsive disorder: Psychobiological approaches to diagnosis, treatment, and pathophysiology, 667
Zubenko GS. Water homeostasis in psychiatric patients, 121-ed
Zubenko GS, Malinakova I, Cohen BM. Temperature dependence of the molecular dynamics of platelet membranes in Alzheimer's disease, 987
Zulley J. *See* Wiegard M

# Subject Index to Volume 22

Abstracts
  appearance of, 1504-le
Acetylcholinesterase, 1097
ACTH *See* Adrenocorticotrophic hormone (ACTH)
Acyclovir
  in schizophrenia, 216
Adolescents
  EEG analysis in, 199
β-Adrenergic agonists
  5-HT receptors and, 529-le
Adrenocorticotrophic hormone (ACTH)
  in hypercortisolemia, 1243
Adrenoleukodystrophy, 1375
Affect
  and catecholamines in elderly schizophrenics, 139
Affective disorders
  cingulotomy in, 807
  cognitive changes in, 979
  in congenital adrenal hyperplasia, 767
  CT of brain density in, 15
  CT of ventricles and sulci in, 4
  HLA A26-B38 in, 221
  HPA axis and, 245-ed
  obsessive-compulsive disorder as, 667
  PET of temporal cortex in, 545
  serial neuroendocrine tests in, 559
Age
  DST and, 1029
Agoraphobia
  DST in, 517
  [$^3$H]imipramine binding in, 59
  and panic disorder, 1491
Alanine
  ventricular enlargement and, 413
Alcoholism
  late positive component in, 848
  prostaglandins and phospholipids in, 1087
Alprazolam
  in depression with panic attacks, 762
Alzheimer's disease
  calcium uptake in, 1079
  lecithin and piracetam in, 112-le
  plasma volume in, 114-le
  platelet membranes in, 987
  prolactin response to TRH in, 661-le
  RS 86 in, 1067
Amineptine
  chlorimipramine vs., 287
Amino acid(s)
  in schizophrenia, 413
  L-tryptophan ratio in depression diagnosis, 177
Amitriptyline
  cholinergic effect of, 495
  cholinergic overdrive during withdrawal, 1485
Amnesia
  animal model of, 593
D-Amphetamine, 1357
Amygdaloid kindled seizures, 1444
Analysis of variance, 665-ed
Androstenone
  olfactory sensitivity to, 922
Anhedonia
  depression vs. schizophrenia in, 829
Anorexia nervosa
  caloric requirements in, 1253
  cerebral glucose metabolism in, 43
  hormonal response to TRH in, 167
Anticholinergic agents
  memory and, 699
Antidepressant(s)
  calcium distribution and, 892
  captopril as, 1274
  cholinergic overdrive during withdrawal of, 1485
  CSF formation and, 892
  in elderly, 733
  5-HT uptake and, 287
  [$^3$H]imipramine binding and, 287
  obsessive-compulsive disorder and, 667
  serotonin potentiation and, 205
Antipsychotic agents
  vasopressin and, 453
Anxiety
  locus coeruleus and, 116-le
Anxiety disorder
  habituation in, 653
  [$^3$H]imipramine binding in, 59
Apomorphine
  growth hormone response and family in schizophrenia, 717
Appetite
  imipramine and, 529

*Abbreviations*
ed: Editorial
le: Letter to the Editor

Arecoline
heart rate response to, 1473
Arrhythmias
chlorpromazine vs. haloperidol and, 1417
Atropine
induced seizures and, 1444
Auditory event-related potentials
augmenting/reducing of, 1413
P3 in fragile X syndrome, 303
in schizophrenia, 440
Augmenting/reducing, 1413
Autism
cholinesterase and, 234
5 HIAA, serotonin, and tryptophan in, 933
Autoantibodies
in discrete areas of brain, 1488
Avoidance
electroconvulsive shock and, 593

Babinski response
nocturnal myoclonus as, 1271
Behavior
D-amphetamine and, 1357
circling, 995
frontal lobe dysfunction in epilepsy and, 1055-le
immune response and, 776
self-injurious, 899
Bender, Lauretta, 1040
Bereavement
cortisol and separation anxiety in, 148
Beta-adrenergic receptors
lithium and, 1191
in manic-depressive illness, 1439
Bipolar disorder
beta-adrenergic receptors in, 1439
cerebral asymmetry in, 1058
prolactin response to metoclopramide in, 508
Blushing
clonidine treatment of, 369
Brain
density in affective disorders, 15
measurements in affective disorders, 4
serum autoantibodies in, 1488
Bromocriptine
in neuroleptic resistance, 523-le
Bulimia
caloric requirements in, 1253
DST in, 783
hormonal responses in TRH in, 167
sleep EEG in, 820

Caffeine
ECT and, 637
Calcium
in Alzheimer's disease, 1079
antidepressants and, 892
Caloric requirements
in eating disorder subtypes, 1253
Captopril
as antidepressant, 1274
Carbamazepine
motor activity and, 941
in obsessive-compulsive disorder, 1169
Cardiac effects
of arecoline infusion, 1473
of chlorpromazine vs. haloperidol, 1417
of thioridazine, 99
Catecholamines
in depression subtypes, 1469
in elderly schizophrenics, 139
Cerebral asymmetry
in bipolar disorder, 1058
Cerebrospinal fluid (CSF)
antidepressants and formation of, 892
in schizophrenia, 413
Ceruletide
in tardive dyskinesia, 797-le
Chemical elements, 805-ed
Children
methylphenidate in, 126
China
reduced haloperidol/haloperidol ratios in, 1406
Chlorimipramine
5-HT uptake and imipramine binding after, 287
Chlorpromazine
heart rate and, 1417
vasopressin and, 453
Choline
lithium and metal ions and, 660-le
Cholinergic effect
of amitriptyline, 495
of amitriptyline withdrawal, 1485
of arecoline, 1473
of cold stress, 1051-le
of shock, 914
Cholinesterase
autism and, 234
Chorea
measurement of, 771
mental status correlation in Huntington's disease, 751
Choreometer, 771
Cingulotomy, 807
Circling behavior
in schizophrenia, 995

Clinical correlates
of sleep onset REM periods in depression, 1477
Clomipramine
in obsessive-compulsive disorder, 667
Clonidine
in social phobia, 369
Cognitive function
affective illness and, 979
catecholamines in elderly schizophrenics and, 139
ECT dosage and, 249
tardive dyskinesia and, 393
Cold stress
cholinergic activity and, 1051-le
Computed tomography (CT)
in adrenoleukodystrophy, 1375
and birth seasonality in schizophrenia, 1288
of brain density in affective disorders, 15
and glutathione in schizophrenia, 1349
of ventricular and sulcal measurements in affective disorders, 4
Conditioning
haloperidol behavioral effect and, 269
Conduct disorder
dopamine and, 1158
Congenital adrenal hyperplasia
organic affective disorder in, 767
Copper
Gilles de la Tourette syndrome and, 968
Core temperature
decrease in as indicator of cholinergic overdrive, 1485
Corpus callosum
in schizophrenia, 1043-le
Correlation coefficients, 926-le
CORRESPONDENCE
β-Adrenergic agonists and 5-HT receptors (with response), 929
Bromocriptine in neuroleptic resistance, 523
Cold stress and cholinergic supersensitivity, 1051
Corpus callosum in schizophrenia (with response), 1043
Diurnal mood variation and REM latency in depression (with response), 800, 1045
Dosage, threshold, and duration of ECT (with response), 1293, 1294
The geography of DST, 1044
Gliosis in schizophrenia (with response), 1172
The history of lithium, 522
5-HT and the functional approach (with response), 1503
Hypoglycemic effect of lithium, 798
Lack of weight gain under desipramine, 796
Lecithin and piracetam in Alzheimer's disease, 112
Lithium discontinuation, serum cortisol, and 5-HTP, 240
Lithium, metal ions, and choline, 660
Locus coeruleus and anxiety (with response), 116
Long-term outcome of neuroleptic malignant syndrome, 239
Maybe handwriting would help, 1504
NMR chemistry of red blood cell constituents, 396
Pearson's correlation coefficient, *p*-value, and lithium therapy, 926
Plasma volume in senile and presenile Alzheimer's disease, 114
Prolactin response to TRH in Alzheimer's disease, 661
Sequelae of neuroleptic malignant syndrome, 237
Tardive dyskinesia after low-dose haloperidol, 111
Temperature regulation and dopamine in schizophrenia, 1048
Thioridazine and neuroleptic malignant syndrome, 1296
Ultradian sleep rhythms and cortisol (with response), 928
Cortical stress test
in schizophrenia, 1304
Corticotropin-releasing hormone
DST and, 228
Cortisol
age and, 1029
free cortisol/18-OH-DOC ratio vs. DST, 947
hypersecretion of, 1243
lithium discontinuation and, 240-le
multiple depressive episodes and, 583
in psychotic depression, 24
RS 86 and, 573
and separation anxiety in bereavement, 148
severity of depression and, 1137
treatment effects on, 213
ultradian sleep rhythm and, 928-le
variations of in response to stress, 1327
Counseling
dietary with naltrexone for obesity, 35
CSF. *See* Cerebrospinal fluid (CSF)
CT. *See* Computed tomography (CT)
Cushing's syndrome
psychiatric patients and, 1264

Dementia
and chorea in Huntington's disease, 751
depression vs., 189
Depression
alprazolam and phenelzine in, 762

anhedonia and, 829
arecoline and, 1473
carbamazepine and motor activity in, 941
catecholamine metabolites in, 1469
clinical correlates of sleep onset REM periods in, 1477
dementia vs., 189
DST-MHPG·$SO_4$ determinations in, 883
DST nonsuppression and, 360
ECT in, 629, 1155
free cortisol/18-OH-DOC ratio in, 947
growth hormone response to GHRH in, 1495
HPA axis response to hypoglycemia in, 153
imipramine effects on appetite in, 529
methylene blue in, 657
multiple and DST, 583
pain syndromes and, 403
panic disorder and, 332, 762, 1491
parkinsonism and, 386
perceptual aberrations and, 829
phenelzine effect on thyroid function in, 1033
prediction of subtype and severity in, 177
prolactin response to metoclopramide in, 508
psychomotor responsivity in, 313
REM latency family concordance in, 910
REM latency in, 800-le, 872, 1045-le, 1477
right hemisphere in, 1201
serial neuroendocrine tests in, 559
severity of and DST, 1137
sleep disturbances in, 513
sleep prolactin secretion in, 1216
taste and smell perception in, 1481
urinary free cortisol in, 24
verapamil in, 779
Desipramine
in dementia-depression distinction, 189
in obsessive-compulsive disorder, 667
weight gain and, 796
Dexamethasone
bioavailability of, 373
concentration of, 957
oral vs. intravenous administration of, 1340
treatment effects on, 213
"window" of, 1035
Dexamethasone Suppression Test
age and, 1029
in agoraphobia, 517
in bulimia, 783
corticotropin-releasing hormone and, 228
Cushing's syndrome evaluation after, 1264
in dementia-depression distinction, 189
depression subtype and severity prediction by, 177
dexamethasone bioavailability and, 373
dexamethasone concentration and, 957
dexamethasone "window" and, 1035
diagnostic utility of, 618
ECT and, 463
EEG abnormalities and, 1151
free cortisol/18-OH-DOC ratio vs., 947
geography of, 1044-le
HPA axis and, 245-ed
in India, 792
lack of effects of hospitalization and oral contraceptives, 1499
and major depressive disorder, 1495
MHPG·$SO_4$ determination with, 883
multiple depressive episodes and, 583
nonsuppression in, 360
oral vs. intravenous drug administration in, 1340
in panic and depressive disorders, 332, 1491
in panic disorder or agoraphobia, 517, 1491
in parkinsonism, 386
REM latency and, 872
in schizophrenia, 792
serial, 559
severity of illness and, 1137
Dietary counseling
with naltrexone for obesity, 35
Diffusion
lithium isotope effects and, 73
Diurnal variation
REM latency and, 800-le, 1045-le
Dopamine
emotional disturbance and, 1158
and temperature regulation in schizophrenia, 1048-le
Dopaminergic activity
in schizophrenia, 995
Drug administration
oral vs. intravenous in DST, 1340
DST. *See* Dexamethasone Suppression Test (DST)
Dysphoria
naltrexone and, 710

Eating disorders
caloric requirements in, 1253
hormonal responses to TRH in, 167
ECT. *See* Electroconvulsive therapy (ECT)
EDITORIALS
Columbus, grantmanship, and clinical research, 1301
DST update: The hypothalamic-pituitary-adrenocortical axis and affective illness, 245
ECT: Second generation instruments, 1181
Elementary, dear Watson! 805
Epilepsy, frontal lobe, and personality, 1055
The history of intelligence, 1425
5-HT, a neurotransmitter for all seasons? 1

The irrationals, 401
Towards psychiatric détente, 525
Two modest proposals, 665
Water homeostasis in psychiatric patients, 121
What is sleep? 931
EEG. *See* Electroencephalography (EEG)
Elderly
antidepressants in, 733
catecholamines and schizophrenia in, 139
nortriptyline and kidney function in, 1283
sleep apnea in, 741
Electroconvulsive shock
avoidance after, 593
Electroconvulsive therapy (ECT)
caffeine and, 637
in depression with white matter hyperintensity, 629
dosage-seizure relations in, 249, 1293-le, 1294-le
DST and, 463
equipment for, 1181-ed
MAO and, 1155
Electroencephalography (EEG)
of adolescents, 199
in bulimia, 820
DST and, 1151
field changes in schizophrenia, 440
frontal in schizophrenia, 102
β-Endorphins
severity of depression and, 1137
Epilepsy
frontal lobe dysfunction in, 1055-ed
model of, 1444
Eye tracking dysfunction, 919

Family
and growth hormone response in schizophrenia, 717
REM latency concordance in, 910
schizophrenia and, 329
Food preference
imipramine and, 529
Fragile X syndrome
P3 abnormality in, 303
Frontal lobe
and behavior in epilepsy, 1055-ed
in schizophrenia, 1021
Functional approach, 1503-le

GABA, 725
Genetics, 1388
Gilles de la Tourette syndrome
copper and, 968
Gliosis
in schizophrenia, 1172-le, 1459
Glucose metabolism
in anorexia nervosa, 43
methylphenidate and, 126
temporal cortex, 545
Glutathione peroxidase
in schizophrenia, 1349
Grants, 1301-ed
Growth hormone
apomorphine response and family in schizophrenia, 717
in major depressive disorder, 1495
TRH response in eating disorders, 167

Habituation
in anxiety disorder, 653
Haloperidol
in Chinese patients, 1406
conditioning and behavioral effects of, 269
heart rate and, 1417
induced seizures and, 1444
reduced haloperidol and, 1369
tardive dyskinesia after, 111-le
vasopressin and, 453
Heart rate
arecoline and, 1473
chlorpromazine vs. haloperidol effect on, 1417
laboratory-induced panic attacks and, 554
Hematocrit
in schizophrenia, 907
5-HIAA. *See* 5-Hydroxyindoleacetic acid (5-HIAA)
HLA haplotype A26-B38, 221
Homovanillic acid
depression subtype and, 1469
haloperidol and, 1369
in pain syndromes, 403
Hormonal probe
of serotonin, 86
HPA axis. *See* Hypothalamic-pituitary-adrenal (HPA) axis
5-HT
β-adrenergic agonists and, 929-le
antidepressants and, 287
behavior and, 1-ed
function and, 1503-le
melancholia and, 1429
Huntington's disease
chorea-dementia correlation in, 751
chorea measurement in, 771
18-Hydroxy-11-deoxycorticosterone (18-OH-DOC)
free cortisol ratio vs. DST, 947
5-Hydroxyindoleacetic acid
autism and, 933
Hyperactivity
methylphenidate action in, 126
Hypercortisolemia, 1243

Hypoglycemia
HPA axis response to in depression, 153
lithium and, 798-le
Hyponatremia
masking schizophrenia, 651
Hypothalamic-pituitary-adrenal (HPA) axis
affective disorders and, 245-ed
hypoglycemia response in depression, 153
interferon and, 1163
severity of depression and, 1137
suicide and, 1409

Imipramine
appetite and food preference effects of, 529
induced seizures and, 1444
[$^3$H]Imipramine binding
in agoraphobia, 59
antidepressants and, 287
in anxiety disorder, 59
in panic disorder, 52, 59
in psychiatric disorders, 278
Immune response
to autoantibodies in normals and schizophrenics, 1488
dominant behavior and, 776
in schizophrenia, 1025
India
DST in, 792
Infant separation distress, 786
Information processing
spatiotemporal in schizophrenia, 688
Insulin hypoglycemia
HPA axis response in depression, 153
Intelligence
the history of, 1425-ed
Interferon
HPA system and, 1163
REM latency and, 104
Irrationality, 401-ed
Isoproterenol panic induction
MHPG levels and, 1127

Kidney function
and nortriptyline in elderly, 1283

Lactate panic induction
MHPG levels and, 1127
sleep, 789
Late positive component
in alcoholism and schizophrenia, 848
Laterality
affective disorders and, 979
augmenting/reducing in evoked potentials and, 1413
depression and, 1201
Lecithin
with piracetam in Alzheimer's disease, 112-le
Light
melatonin production and, 473
Limbic system
procaine as probe of, 1107
Lithium
cortical phospholipids and, 540
discontinuation effects of, 240-le
erythrocyte membrane effects of, 857
history of, 522-le
hypoglycemia and, 798-le
isotope effects of, 73
metal ions and, 660-le
myoclonic seizures with, 1184
research methodology and, 926-le
retina and pineal gland beta receptors and, 1191
Locus coeruleus
anxiety and, 116-le
Lymphocytes
calcium uptake by in Alzheimer's disease, 1079
muscarinic cholinergic receptors on, 1451

Mania
negative air ions and, 107
MAO. *See* Monoamine oxidase (MAO)
Maprotiline
chlorimipramine vs., 287
Medical education, 665-ed
Melancholia
and growth hormone response, 1495
serotonin in, 1429
Melatonin
light and production of, 473
Memory
schizophrenia and, 79
Metal ions
choline transport and, 660-le
Methamphetamine
induced seizures and, 1444
Methylene blue
in depression, 657
Methylphenidate
brain energy metabolism of, 126
Metoclopramide
prolactin response in depression and bipolar disorder, 508
MHPG
in conduct disorder, 1158
depression subtype and severity prediction by, DST with, 883
in induced anxiety states, 1127
in untreated panic disorder, 1491
Minor physical anomalies
violence and, 1166

Mitral valve prolapse
panic disorder and, 339
Molecular genetics, 1388
Monoamine oxidase (MAO)
ECT and, 1155
Motor activity
carbamazepine and, 941
visual in schizophrenia, 1227
Muscarinic agonists
cortisol response to, 573
Muscarinic cholinergic receptors, 1451

Naloxone
self–injurious behavior and, 899
Naltrexone
with counseling for obesity, 35
dysphoria and, 710
Naps
sleep deprivation therapy and, 389
Negative air ions
in mania, 107
Neuroendocrine tests
serial in depression, 559
Neuroleptic(s). *See also specific agent*
bromocriptine and, 523-le
induced seizures and, 1444
memory and, 699
parkinsonism from, 427
PET of, 479
Neuroleptic malignant syndrome, 1004
sequelae of, 237-le, 239-le
thioridazine and, 1296-le
Neurologic abnormalities
schizophrenic family history and, 325
Nicotine
tardive dyskinesia and, 67, 1280
NMR. *See* Nuclear magnetic resonance (NMR)
Nocturnal myoclonus, 1271
Nortriptyline
and kidney function in elderly, 1283
Nuclear magnetic resonance (NMR)
of red blood cell constituents, 396

Obesity
naltrexone and counseling for, 35
Obsessive–compulsive disorder, 667
carbamazepine in, 1169
18-OH-DOC. *See* 18-Hydroxy-11-deoxycorticosterone
Olfactory sensitivity
in schizophrenia, 922
Oral contraceptives
lack of effect on the DST, 1499

P3 auditory event-related potential
in fragile X syndrome, 303
Pain syndromes
serotonergic and dopaminergic systems in, 403
Panic disorder
alprazolam and phenelzine in, 762
arecoline in, 1473
biological markers in, 339
depression and, 332, 762
DST in, 517
[$^3$H]imipramine binding in, 52, 59
lactate induction of, 789
MHPG and, 1127, 1491
preinfusion heart rate in, 554
Parkinsonism
DST in, 386
neuroleptic-induced in schizophrenia, 427
Peer review, 1301-ed
Perceptual aberration
depression vs. schizophrenia in, 829
PET. *See* Positron emission tomography (PET)
Phenelzine
in depression with panic attacks, 762
thyroid function and, 1033
Phenylalanine
in schizophrenia, 194
Phenylethylamine
in schizophrenia, 194
Phospholipase-A2
in schizophrenia, 421
Phospholipids
lithium and, 540
and prostaglandins in violent offenders, 1087
Pineal gland
lithium and beta receptors in, 1191
PIP syndrome
water balance variation in, 224
Piracetam
with lecithin in Alzheimer's disease, 112-le
Plasma volume
in Alzheimer's disease, 114-le
Platelet [$^3$H]imipramine binding
in agoraphobia, 59
antidepressants and, 287
in anxiety disorder, 59
in panic disorder, 52, 59
in psychiatric disorders, 278
Platelet membranes
in Alzheimer's disease, 987
Polydipsia, 121-ed
PIP syndrome and, 224
Positron emission tomography (PET)
in anorexia nervosa, 43
of neuroleptics, 479
temporal cortex, 545
Procaine
as limbic system probe, 1107

Prolactin
metoclopramide response in depression and bipolar disorder, 508
TRH response in Alzheimer's disease, 661-le
TRH response in eating disorders, 167
sleep secretion of in depression, 1216
Prostaglandins
in violent offenders, 1087
Pseudocholinesterase, 1238
Psychiatric disorder
adrenoleukodystrophy presenting as, 1375
Psychiatric patients. *See also specific disorder*
acetylcholinesterase in, 1097
Cushing's syndrome evaluation in, 1264
eye tracking in, 919
imipramine binding in, 278
limbic system probe in, 1107
PIP syndrome in, 224
pseudocholinesterase in, 1238
sensory gating in, 603
water homeostasis in, 121-ed
Psychiatry
détente in, 525-ed, 526-ed
molecular genetics in, 1388
Psychomotor responsivity
in depression, 313
Psychotic depression
urinary free cortisol in, 24
Rapid eye movement
*See* REM latency
*See* REM sleep
Rats
genetically fearful, 787
Red blood cells
acetylcholinesterase, 1097
lithium membrane effects on, 857
NMR of, 396-le
Regional cerebral blood flow
in schizophrenia, 1304
REM latency
clinical correlates in depression, 1477
concordance of in depressed family members, 910
diurnal mood variations and, 800-le, 1045-le
DST and, 872
REM sleep
clinical correlates in depression, 1477
cortisol and, 928
interferon and, 104
Reserpine
induced seizures and, 1444
Retina
lithium and beta receptors in, 491
Right hemisphere
in depression, 1201
RS 86
in Alzheimer's disease, 1067
cortisol system effects of, 573
Scanning
in schizophrenia, 1227
Schizophrenia
acyclovir in, 216
anhedonia and, 829
antipsychotics and vasopressin in, 453
apomorphine-growth hormone response and family in, 717
birth seasonality and CT in, 1288
catecholamines in, 139
circling behavior in, 995
corpus callosum in, 1043-le
cortical stress tests in, 1304
CSF amino acids in, 413
DST in, 792
EEG field changes in, 440
family and, 325
gliosis in, 1172-le, 1459
glutathione peroxidase in, 1349
hematocrit in, 907
hypofrontality in, 1021
late positive component in, 848
memory and, 79, 699
neuroleptic-induced parkinsonism in, 427
olfactory sensitivity in, 922
perceptual aberration and, 829
PET of neuroleptics in, 479
phenylethylamine and phenylalanine in, 194
phospholipase-A2, 421
sensory gating in, 603
serum autoantibodies in, 1488
Spatiotemporal processing in, 688
T cells in, 1025
temperature regulation and dopamine in, 1048-le
visuomotor performance in, 1227
water intoxication masking, 650
Seasonality
of birth in schizophrenia, 1288
Seizures
caffeine and, 637
ECT dosage and, 249, 1293-le, 1294-le
kindled, 1444
myoclonic with lithium, 1184
Self-injurious behavior
naloxone and 899
Sensory gating, 603
Separation anxiety
and cortisol in bereavement, 148
infant in fearful rats, 786
Serotonin
autism and, 933
hormonal probes of, 86

lithium discontinuation and, 240-le
melancholia and, 1429
obsessive-compulsive disorder and, 667
pain syndromes and, 403
potentiation of, 205
Shock
avoidance after, 593
cholinergic effects of, 914
Sleep
Babinski-like response in, 1271
clinical correlates in depression, 1477
cortisol and ultradian rhythms of, 928-le
EEG in bulimia, 820
hypothalamic modulation of in depression, 513
interferon and REM latency in, 104
lactate infusion during, 789
nature of, 931-ed
Sleep apnea
in elderly, 741
Sleep deprivation therapy
naps and, 389
Smell perception in depression, 1481
Smoking
tardive dyskinesia and, 67, 1280
Social phobia
clonidine in, 369
Sodium homeostasis
in PIP syndrome, 224
Spatiotemporal processing
in schizophrenia, 688
Stigmata
violence and, 1166
Stress tests
cortical in schizophrenia, 1304
variation in cortisol response to, 1327
Suicide
cingulotomy and, 807
pituitary-adrenal function and, 1409
Sulci
CT measurements in affective disorders, 4

T cells
in schizophrenia, 1025
Tardive dyskinesia
ceruletide in, 797-le
cognitive function and, 393
after low-dose haloperidol, 111-le
nicotine exposure and, 67, 1280
Taste and smell perception in depression, 1481
Temperature
cholinergic activity and, 1051-le
and dopamine in schizophrenia, 1048-le
and platelets in Alzheimer's disease, 987
Temporal lobe
gliosis in, 1459
Theophylline-sensitive T-lymphocytes
in schizophrenia, 1025
Thioridazine
neuroleptic malignant syndrome and, 1296-le
torsade de pointes and, 99
Thyroid function
phenelzine and, 1033
Thyrotropin
TRH response in eating disorders, 167
Thyrotropin-releasing hormone (TRH)
hormonal responses in eating disorders, 167
prolactin response in Alzheimer's disease, 661-le
Thyrotropin-releasing hormone test
in depression-dementia distinction, 189
serial in depression, 559
Torsade de pointes
thioridazine and, 99
Treatment effects, 213
TRH. *See* Thyrotropin-releasing hormone (TRH)
Tryptophan
amino acid ratio in depression diagnosis, 177
autism and, 933
Untreated panic disorder
plasma MHPG in, 1491
Urinary free cortisol
in bereavement, 149
in psychotic depression, 24
USSR
psychiatry in, 525-ed, 526-ed

Vasopressin
antipsychotics and, 453
retention deficits and, 593
Ventricles
CT measurements in affective disorders, 4
in schizophrenia, 413
Verapamil
in depression, 779
Violence
minor physical anomalies and, 1166
phospholipids and prostaglandins in, 1087
Visual evoked potentials
augmenting/reducing of, 1413
Visuomotor function
in schizophrenia, 1227

Water homeostasis
in PIP syndrome, 224
in psychiatric patients, 121-ed
Water intoxication
masking schizophrenia, 650
Weight gain
desipramine and, 796-le
White matter hyperintensity, 629